Tarcocimab DAYLIGHT Phase 3 nAMD Topline
Phase 3 efficacy readout for tarcocimab in wet AMD. Tarcocimab missed primary endpoints in two prior Phase 3 trials (BEACON for RVO, GLOW for DR). Watch: BCVA non-inferiority vs. aflibercept (Eylea).
What’s at stake
Tarcocimab tedromer is an anti-VEGF therapy developed by Kodiak Sciences using a novel antibody-biopolymer conjugate platform designed to extend the duration of action in retinal disease and reduce the frequency of intravitreal injections. The active antibody inhibits VEGF — the driver of abnormal retinal blood vessel growth in wet AMD and diabetic macular edema — while the biopolymer prolongs retention in the eye toward a 6-month dosing interval. Standard anti-VEGF drugs require injections every 1–3 months; tarcocimab has missed primary endpoints in two prior Phase 3 programs and is in a new pivotal trial for wet AMD versus aflibercept.
No primer in glossary yet.
Prior KOD reactions to Readout events
| Date | Headline | Outcome | 1W | 1M | 6M |
|---|---|---|---|---|---|
| May 2025 | tarcocimab tedromer — Phase 2b Topline Met Primary Endpoint | positive | +27.3% | +41.8% | +36.2% |
| Mar 2025 | tarcocimab tedromer — Phase 2b Topline Met Primary Endpoint | negative | -29.4% | -27.5% | -15.0% |
Disclosure trail
- Apr 4, 2026·26d agopinned · highest confidenceHIGH conf8-KWINDOW↗ 61dvs priortop claimAUG–AUG2026
“Following completion of additional masked image adjudication, the Company now expects to report DAYLIGHT topline results in late Q3 2026.”
conf 91%via llm - Feb 25, 2026·2mo agoMED conf8-KWINDOWother claimJUN–JUN2026
“We continue to expect DAYLIGHT topline data in mid-2026.”
conf 83%via llm